Join        Login             Stock Quote

StemCells (STEM) Shares Jump After Data From Spinal Cord Injury Trial

 February 12, 2013 01:44 PM

(By Balaseshan) StemCells Inc. (NASDAQ: STEM) shares jumped nearly 28% after the company said its product candidate for chronic spinal cord injury continued to show a favorable safety profile.

The company said the first patient cohort completed Phase I/II spinal cord injury trial and "considerable" gains in sensory function persisted in two of the three patients twelve months after stem cell transplant. The persistence of these sensory gains at the 12-month evaluation was seen across more than one clinical measure.

One patient converted from a complete to an incomplete injury between the six- and 12-month evaluations, the developer of stem cell therapeutics said.

[Related -Stocks End Mixed Ahead Of Obama Address; Avon Products (AVP) Surges]

"While we need to be cautious when interpreting data from a small, uncontrolled trial, to our knowledge, this is the first time a patient with a complete spinal cord injury has been converted to a patient with an incomplete injury following transplantation of neural stem cells," said Armin Curt, principal investigator of the clinical trial. "We are encouraged that the cells appear to convey clinical benefit in such severely injured patients."

By completing the twelve-month assessment, the company said the first patient cohort has now completed the trial, and has entered into a separate follow-up study for long-term observation.

The company plans to follow the effects of this therapy long-term, and each of the patients will be invited to enroll into a separate four-year observational study after completing the Phase 1/2 study.

[Related -Very Nasty Day On Wall Street]

STEM is currently trading up 24.62% at $2.05 on Tuesday. The stock has been trading between $0.59 and $2.67 for the past 52 weeks.



Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageTackling China's Debt Problem: Can Debt-Equity Conversions Help?

China’s high and rising corporate debt problem and how best to address it has received much attention read on...

article imageWill Job Growth Kill The Bear-Market Signal For Stocks?

It’s all about jobs now. Actually, it’s always been about jobs. But the stakes are even higher—perhaps more read on...

article imageAutomating Ourselves To Unemployment

In this current era of central planning, malincentives abound. We raced to frack as fast we could for the read on...

article imageFed: Waiting For June… Or Godot?

The Federal Reserve left interest rates unchanged yesterday, as widely expected. But the possibility of a read on...

Popular Articles

Daily Sector Scan
Partner Center

Related Articles:

A Comeback, But Technicals Remained Negative
More Articles on: Medical

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.